Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17731192 | 1.00 | OPRL1 (0.50) | OPRL1GPBAR1MEN1KMT2ADGAT1 | |
| SCHEMBL2254089 | 0.86 | DGAT1 (0.43) | OPRL1DGAT1JAK2JAK1TYK2 | |
| SCHEMBL2254093 | 0.86 | DGAT1 (0.43) | OPRL1DGAT1JAK2JAK1TYK2 | |
| SCHEMBL5535425 | 0.86 | DGAT1 (0.43) | OPRL1DGAT1JAK2JAK1TYK2 | |
| SCHEMBL17731210 | 0.84 | KMT2A (0.45) | MEN1KMT2ADGAT1JAK2JAK1 | |
| SCHEMBL28171774 | 0.82 | JAK2 (0.43) | MEN1KMT2ADGAT1JAK2JAK1 | |
| SCHEMBL17730953 | 0.82 | BRD4 (0.46) | MEN1KMT2AJAK2JAK1TYK2 | |
| SCHEMBL27171506 | 0.82 | OPRL1 (0.54) | OPRL1GPBAR1DGAT1 | |
| SCHEMBL28171054 | 0.80 | JAK2 (0.43) | DGAT1JAK2JAK1TYK2JAK3 | |
| SCHEMBL2257942 | 0.79 | HSD17B1 (0.43) | OPRL1MEN1KMT2ADGAT1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | OPRL1 1082/4885GPBAR1 795/4885MEN1 3659/4885 |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | OPRL1 1082/4885GPBAR1 795/4885MEN1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.